Weigel, Lucia
Wehr, Sophia
Galderisi, Silvana http://orcid.org/0000-0002-1592-7656
Mucci, Armida http://orcid.org/0000-0002-6195-9456
Davis, John http://orcid.org/0000-0003-3963-1654
Giordano, Giulia Maria http://orcid.org/0000-0002-5247-1117
Leucht, Stefan http://orcid.org/0000-0002-4934-4352
Article History
Received: 28 April 2023
Accepted: 17 July 2023
First Online: 27 July 2023
Competing interests
: The authors declare the following competing interests: S.G. received advisory board/consultant fees, or honoraria/expenses from the following drug companies: Angelini, Boehringer Ingelheim, Gedeon Richter-Recordati, Innova Pharma-Recordati Group, Janssen, Lundbeck, Otsuka, Recordati Pharmaceuticals, Rovi Pharma and Sunovion Pharmaceuticals outside the submitted work. A.M. received advisory board or consultant fees from the following drug companies: Angelini, Gedeon. Richter Bulgaria, Janssen Pharmaceuticals, Lundbeck, Otsuka Pharmaceutical, Pfizer, Pierre Fabre, Rovi. Pharma and Boehringer Ingelheim outside the submitted work. S.L. has received honoraria as a consultant and/or advisor and/or for lectures and/or for educational material from Alkermes, Angelini, Eisai, Gedeon Richter, Janssen, Lundbeck, Medichem, Medscape, Merck Sharpp and Dome, Mitshubishi, Neurotorium, NovoNordisk, Otsuka, Recordati, Roche, Rovi, Sanofi Aventis, TEVA in the last three years. L.W., S.W., J.D. and G.M.G. have no conflict of interests to declare.